Ketamine Study Finds Brain Response May Depend on the Patient
Ketamine has often been discussed as a fast acting treatment with unusually broad potential in mental health care. A new study published in Biological Psychiatry adds a more precise question to that conversation. The issue may not only be whether ketamine changes the brain. It may be how each person’s brain responds before treatment begins.
New:Â Interested in Being Part of a Psychedelics-Focused Clinical Trial? Sign Up Here
| Key takeaway | What it means |
|---|---|
| Ketamine did not produce one uniform brain effect | Some participants showed one pattern, while others showed the opposite pattern |
| EEG testing may help predict response | A baseline brain measure appeared to forecast the direction and size of ketamine’s effect |
| The study focused on healthy volunteers | The findings are early and need more clinical research in patients |
| The work may matter for depression care | It could help explain why some people respond to ketamine and others do not |
| Personalized psychiatry may be the larger goal | Brain based markers could eventually help guide treatment choices |
Looking for treatment? Find Spravato clinics (which is covered by insurance) and  ketamine clinics closest to you as well as other psychedelic therapies in your area.
A Different Kind of Ketamine Signal
The study examined a brain signal called mismatch negativity amplitude, or MMNa. This signal comes from EEG and event related potential testing, which measures the brain’s electrical response to specific stimuli.
Researchers expected ketamine to reduce MMNa across participants. That has been the traditional assumption in much of the scientific literature.
Instead, the study found something more complicated. Participants with a larger baseline MMNa tended to show a reduction after ketamine. Participants with a smaller baseline MMNa showed an increase.
The researchers called this a disordinal effect. In plain English, ketamine appeared to push the same brain marker in opposite directions, depending on where a person started.
Why This Could Matter For Treatment
Ketamine therapy has changed the landscape for treatment resistant depression. It has also raised a difficult clinical problem. Not everyone responds.
For patients, that uncertainty can carry real weight. Treatment may involve cost, time, medical screening, transportation, and emotional hope. A better way to predict response would matter.
This study does not prove that EEG can determine who should receive ketamine. It also did not test people with depression. The participants were healthy volunteers who received ketamine and placebo across separate visits.
Still, the finding points toward a possible future. A simple baseline brain measure could help clinicians understand who is more likely to respond, and in what direction.
The Bigger Shift Toward Personalized Psychiatry
Mental health treatment still relies heavily on symptoms, history, and trial and error. That approach can work, but it often takes time.
Brain based biomarkers could offer another layer of guidance. They may help researchers design stronger clinical trials. They may also help clinicians avoid treating every patient as if their biology is the same.
For ketamine, that distinction is especially important. The treatment can act quickly, but its effects vary. If EEG can help explain that variation, it could make ketamine care more targeted, more efficient, and more realistic.
The study should be viewed as a step, not a final answer. It gives researchers a clearer path to test the idea in people with depression, PTSD, anxiety, and other conditions where ketamine is already being explored.
The most important takeaway is also the most practical one. Ketamine may not have one brain effect. It may have different effects in different people. The next phase of research will determine whether that insight can improve care.
